e-ISSN: 0976-822X, p-ISSN:2961-6042
A ailable online on h p://www.ijcp .com/
In e na ional Jou nal o Cu en Pha maceu ical Re iew and Resea ch 2025; 17(8); 781-786
Paul e al. In e na ional Jou nal o Cu en Pha maceu ical Re iew and Resea ch
781
O iginal Resea ch A icle
Neoadju an Chemo he apy wi h Weekly Cispla in and Pacli axel
Followed by Chemo adia ion o Locally Ad anced Ce ical Cance
Sou a Paul1, Juhi2
1Senio Residen , MBBS, MD (Radia ion Oncology), Depa men o Radio he apy, R G Ka Medical
College & Hospi al, Kolka a, Wes Bengal 700004
2Junio Residen , MBBS, MD PGT, Depa men o Radio he apy, R G Ka Medical College & Hospi al,
Kolka a, Wes Bengal 700004
Recei ed: 01-06-2025 / Re ised: 16-07-2025 / Accep ed: 13-08-2025
Co esponding Au ho : D . Sou a Paul
Con lic o in e es : Nil
Abs ac
In oduc ion: Locally ad anced ce ical cance (LACC) emains a signi ican he apeu ic challenge, wi h
s anda d ea men in ol ing concu en chemo adia ion. Neoadju an chemo he apy (NACT) be o e
chemo adia ion may imp o e umo sh inkage, acili a e be e local con ol, and educe dis an me as asis. This
s udy e alua es he e icacy and sa e y o weekly cispla in and pacli axel as neoadju an chemo he apy ollowed
by chemo adia ion in pa ien s wi h LACC.
Me hods: This p ospec i e obse a ional s udy was conduc ed o e a pe iod o one yea a R G Ka Medical
College. A o al o 80 pa ien s wi h his ologically con i med locally ad anced ce ical cance (FIGO s ages IB2
o IIIB) we e en olled. Key s udy a iables included pa ien age, FIGO s age, umo his ology, and Eas e n
Coope a i e Oncology G oup (ECOG) pe o mance s a us. Pa ien s ecei ed neoadju an chemo he apy wi h
weekly cispla in and pacli axel ollowed by chemo adia ion. T ea men esponse was assessed using clinical and
adiological pa ame e s, while oxici y was moni o ed and g aded acco ding o s anda d c i e ia. Ou comes
measu ed included umo esponse, oxici y p o ile, p og ession- ee su i al, and o e all su i al.
Resul s: The s udy included 80 pa ien s wi h locally ad anced ce ical cance , p edominan ly FIGO s age IIB
and squamous cell ca cinoma. Following neoadju an chemo he apy wi h weekly cispla in and pacli axel, 85%
o pa ien s achie ed an o e all esponse (30% comple e, 55% pa ial). Tumo size signi ican ly dec eased om
5.4 cm o 3.2 cm (p < 0.001). The ea men was well ole a ed, wi h manageable hema ological and non-
hema ological oxici ies. A 12 mon hs ollow-up, p og ession- ee su i al was 72.5%, and o e all su i al was
85%. Pa ien s wi h comple e o pa ial esponse had signi ican ly be e su i al ou comes han hose wi h s able
o p og essi e disease (PFS: 14 s. 8 mon hs, p = 0.002; OS: 18 s. 11 mon hs, p = 0.004).
Conclusions: Weekly cispla in and pacli axel as neoadju an chemo he apy ollowed by s anda d chemo adia ion
is easible and well ole a ed in LACC pa ien s, wi h encou aging ea ly clinical esponse and su i al ou comes.
Fu he andomized con olled ials a e wa an ed o con i m he bene i o his sequen ial app oach compa ed o
chemo adia ion alone.
Keywo ds: Locally Ad anced Ce ical Cance , Neoadju an Chemo he apy, Cispla in, Pacli axel,
Chemo adia ion, Clinical Response, Toxici y.
This is an Open Access a icle ha uses a unding model which does no cha ge eade s o hei ins i u ions o access and dis ibu ed unde
he e ms o he C ea i e Commons A ibu ion License (h p://c ea i ecommons.o g/licenses/by/4.0) and he Budapes Open Access Ini ia i e
(h p://www.budapes openaccessini ia i e.o g/ ead), which pe mi un es ic ed use, dis ibu ion, and ep oduc ion in any medium, p o ided
o iginal wo k is p ope ly c edi ed.
In oduc ion
Ce ical cance emains one o he leading causes o
cance - ela ed mo bidi y and mo ali y among
women wo ldwide, pa icula ly in low- and middle-
income coun ies. Acco ding o he Wo ld Heal h
O ganiza ion, app oxima ely 600,000 new cases o
ce ical cance a e diagnosed annually, wi h a
majo i y p esen ing as locally ad anced ce ical
cance (LACC) a he ime o diagnosis [1]. LACC,
de ined as In e na ional Fede a ion o Gynecology
and Obs e ics (FIGO) s age IB2 o IIIB, is
cha ac e ized by bulky umo s con ined o he ce ix
and adjacen issues wi hou dis an me as asis. The
managemen o LACC poses signi ican challenges
due o he high isk o local ecu ence and dis an
ailu e despi e ea men [2]. The cu en s anda d o
ca e o LACC is concu en chemo adia ion he apy
(CCRT), which combines ex e nal beam adia ion
he apy (EBRT), in aca i a y b achy he apy, and
weekly cispla in chemo he apy [3]. Cispla in ac s as
a adiosensi ize , enhancing he e icacy o adia ion
he apy by inhibi ing DNA epai in umo cells.
This combined modali y app oach has imp o ed
loco egional con ol and su i al a es compa ed o
adia ion alone. Howe e , ea men ailu e s ill
occu s in app oxima ely 30–40% o pa ien s due o
pe sis en disease o dis an me as ases [4].
In e na ional Jou nal o Cu en Pha maceu ical Re iew and Resea ch e-ISSN: 0976-822X, p-ISSN: 2961-6042
Paul e al. In e na ional Jou nal o Cu en Pha maceu ical Re iew and Resea ch
782
In an e o o imp o e ou comes, neoadju an
chemo he apy (NACT) adminis e ed be o e
chemo adia ion has been explo ed. The a ionale o
NACT is o educe umo bulk, e adica e
mic ome as a ic disease, and imp o e he umo
mic oen i onmen o subsequen adia ion [5].
Ea ly ials wi h NACT demons a ed mixed esul s,
bu ecen ad ances in chemo he apy egimens and
suppo i e ca e ha e enewed in e es in his
app oach [6]. Among he chemo he apy agen s,
cispla in and pacli axel ha e shown syne gis ic
cy o oxici y and adiosensi iza ion e ec s, making
hem a p e e ed combina ion in ce ical cance [7].
Pacli axel, a mic o ubule-s abilizing agen , dis up s
mi o ic spindle o ma ion leading o apop osis, and
has been e ec i ely combined wi h cispla in in
a ious solid umo s. Weekly dosing schedules o
cispla in and pacli axel a e conside ed o balance
e icacy wi h manageable oxici y and main ain dose
in ensi y [8]. This egimen is hypo hesized o
enhance umo esponse p io o adia ion,
po en ially imp o ing long- e m con ol and
su i al.
Se e al ecen s udies ha e e alua ed he e icacy o
NACT wi h weekly cispla in and pacli axel ollowed
by chemo adia ion in pa ien s wi h LACC. Resul s
ha e sugges ed imp o ed umo esponse a es,
dec eased umo size, and a o able oxici y p o iles
[9]. Mo eo e , his sequen ial s a egy may allow o
be e pa ien selec ion and indi idualized ea men
planning based on ea ly chemo he apy esponse.
Howe e , e idence emains limi ed, and op imal
dosing, du a ion, and iming in ela ion o
chemo adia ion equi e u he elucida ion. Despi e
p omising p elimina y da a, he in eg a ion o
NACT wi h weekly cispla in and pacli axel ollowed
by s anda d chemo adia ion is no ye uni e sally
accep ed as s anda d ea men .
Challenges include po en ial inc eased oxici y, isk
o delaying de ini i e adia ion, and lack o la ge
andomized con olled ials demons a ing su i al
bene i . None heless, ongoing clinical ials and
ins i u ional expe iences ha e gene a ed aluable
da a suppo ing he easibili y and po en ial bene i
o his app oach [10]. In summa y, locally ad anced
ce ical cance con inues o ep esen a he apeu ic
challenge despi e ad ances in chemo adia ion.
Neoadju an chemo he apy wi h weekly cispla in
and pacli axel p io o chemo adia ion is an
eme ging s a egy aimed a imp o ing umo
esponse and su i al ou comes. Con inued esea ch
is c i ical o de ine he op imal ea men p o ocols
and es ablish his app oach in ou ine clinical
p ac ice.
Ma e ials and Me hods
S udy Design: P ospec i e obse a ional s udy.
Place o s udy: R G Ka Medical College.
Pe iod o s udy: 1 Yea .
S udy Va iables
• Age
• FIGO S age
• His ology
• ECOG Pe o mance S a us
• Response Ca ego y
• Pa ame e
• Toxici y
• Ou come
Sample Size: 80 Pa ien s wi h his ologically
con i med locally ad anced ce ical cance (FIGO
s ages IB2 o IIIB).
Inclusion C i e ia
• His ologically con i med locally ad anced
ce ical cance (FIGO IB2 o IIIB)
• Age 18-70 yea s
• ECOG pe o mance s a us 02
• Adequa e o gan unc ion ( enal, hepa ic,
hema ologic)
• No p io ea men o ce ical cance
Exclusion C i e ia
• Dis an me as asis o ecu en ce ical cance
• P egnancy o lac a ion
• Se e e como bidi ies con aindica ing
chemo he apy o adio he apy
• Known hype sensi i i y o cispla in o
pacli axel
• P e ious malignancy wi hin 5 yea s (excep
non-melanoma skin cance )
S a is ical Analysis
Con inuous a iables we e exp essed as mean ±
s anda d de ia ion o median wi h in e qua ile
ange, while ca ego ical a iables we e p esen ed as
equencies and pe cen ages. The clinical esponse
a es be o e and a e ea men we e compa ed
using he Chi-squa e es o Fishe ’s exac es as
app op ia e. Su i al ou comes, including
p og ession- ee su i al (PFS) and o e all su i al
(OS), we e es ima ed using he Kaplan-Meie
me hod, and di e ences be ween g oups we e
assessed wi h he log- ank es . A p- alue o less
han 0.05 was conside ed s a is ically signi ican
h oughou he analysis.
Resul
In e na ional Jou nal o Cu en Pha maceu ical Re iew and Resea ch e-ISSN: 0976-822X, p-ISSN: 2961-6042
Paul e al. In e na ional Jou nal o Cu en Pha maceu ical Re iew and Resea ch
783
Table 1: Baseline Pa ien Cha ac e is ics (n=80)
Baseline Pa ien
Cha ac e is ic
Value
Age
Age (mean ± SD, yea s)
49.2 ± 8.7
FIGO S age
IB2
20 (25%)
IIA
15 (18.8%)
IIB
30 (37.5%)
IIIA
10 (12.5%)
IIIB
5 (6.2%)
His ology
Squamous cell ca cinoma
68 (85%)
Adenoca cinoma
12 (15%)
ECOG Pe o mance S a us
0–1
70 (87.5%)
2
10 (12.5%)
Table 2: T ea men Response a e Neoadju an Chemo he apy (n=80)
Response Ca ego y
Numbe (%)
Comple e Response (CR)
24 (30%)
Pa ial Response (PR)
44 (55%)
S able Disease (SD)
10 (12.5%)
P og essi e Disease (PD)
2 (2.5%)
Table 3: Compa ison o Tumo Size Be o e and A e Neoadju an Chemo he apy
Pa ame e
Be o e NACT (cm) Mean ± SD
A e NACT (cm) Mean ± SD
p- alue
Tumo Size
5.4 ± 1.2
3.2 ± 1.0
<0.001
Table 4: Toxici y P o ile Du ing Neoadju an Chemo he apy (n=80)
Toxici y
G ade 1–2, n (%)
G ade 3–4, n (%)
Hema ological (Anemia)
30 (37.5%)
8 (10%)
Neu openia
18 (22.5%)
5 (6.3%)
Nausea/Vomi ing
40 (50%)
6 (7.5%)
Pe iphe al Neu opa hy
12 (15%)
3 (3.8%)
Table 5. Su i al Ou comes a 12 Mon hs Follow-up
Ou come
Numbe (%) / Median (mon hs)
p- alue
P og ession-F ee Su i al (PFS) Ra e
58 (72.5%)
—
O e all Su i al (OS) Ra e
68 (85%)
—
PFS by Response (CR+PR s SD+PD)
Median PFS: 14 s 8 mon hs
0.002 (Log- ank es )
OS by Response (CR+PR s SD+PD)
Median OS: 18 s 11 mon hs
0.004 (Log- ank es )
Figu e 1: Toxici y P o ile Du ing Neoadju an Chemo he apy (n=80)
In e na ional Jou nal o Cu en Pha maceu ical Re iew and Resea ch e-ISSN: 0976-822X, p-ISSN: 2961-6042
Paul e al. In e na ional Jou nal o Cu en Pha maceu ical Re iew and Resea ch
784
Figu e 2: Compa ison o Tumo Size Be o e and A e Neoadju an Chemo he apy
The s udy en olled 80 pa ien s wi h locally ad anced
ce ical cance , wi h a mean age o 49.2 ± 8.7 yea s.
The majo i y o pa ien s p esen ed wi h FIGO s age
IIB (37.5%), ollowed by IB2 (25%), IIA (18.8%),
IIIA (12.5%), and IIIB (6.2%). His ologically,
squamous cell ca cinoma was he p edominan
sub ype, accoun ing o 85% o cases, while
adenoca cinoma ep esen ed 15%. Mos pa ien s
(87.5%) had an Eas e n Coope a i e Oncology
G oup (ECOG) pe o mance s a us o 0–1.
Following neoadju an chemo he apy wi h weekly
cispla in and pacli axel, clinical e alua ion showed
ha 30% o pa ien s (n=24) achie ed a comple e
esponse (CR), while 55% (n=44) demons a ed a
pa ial esponse (PR). S able disease (SD) was
obse ed in 12.5% (n=10) o pa ien s, and
p og essi e disease (PD) occu ed in 2.5% (n=2).
An o e all esponse a e (CR + PR) o 85%.
The mean umo size be o e neoadju an
chemo he apy (NACT) was 5.4 ± 1.2 cm, which
signi ican ly dec eased o 3.2 ± 1.0 cm a e
comple ion o NACT (p < 0.001). This s a is ically
signi ican educ ion demons a es he e ec i eness
o weekly cispla in and pacli axel in sh inking umo
bu den p io o chemo adia ion.
Neoadju an chemo he apy wi h weekly cispla in
and pacli axel was gene ally well ole a ed.
Hema ological oxici ies included anemia, obse ed
in 37.5% o pa ien s wi h g ade 1–2 se e i y and
10% expe iencing g ade 3–4 anemia. Neu openia
occu ed in 22.5% o pa ien s a g ade 1–2 and 6.3%
a g ade 3–4. Non-hema ological oxici ies included
nausea and omi ing in 50% o pa ien s (g ade 1–2)
and 7.5% (g ade 3–4). Pe iphe al neu opa hy was
no ed in 15% o pa ien s wi h mild o mode a e
symp oms and 3.8% wi h se e e symp oms
A a median ollow-up o 12 mon hs, he
p og ession- ee su i al (PFS) a e was 72.5%
(n=58), and he o e all su i al (OS) a e was 85%
(n=68). Pa ien s who achie ed comple e o pa ial
esponse (CR+PR) a e neoadju an chemo he apy
exhibi ed signi ican ly longe median PFS (14
mon hs) compa ed o hose wi h s able o
p og essi e disease (SD+PD), who had a median
PFS o 8 mon hs (p = 0.002). Simila ly, median OS
was signi ican ly imp o ed in he CR+PR g oup a
18 mon hs e sus 11 mon hs in he SD+PD g oup (p
= 0.004).
Discussion
In his s udy o 80 pa ien s wi h locally ad anced
ce ical cance (LACC), neoadju an chemo he apy
(NACT) using weekly cispla in and pacli axel
ollowed by chemo adia ion showed p omising
clinical ou comes wi h a high o e all esponse a e
o 85%, signi ican umo size educ ion, accep able
oxici y, and encou aging su i al a es. The mean
age o 49.2 yea s and p edominance o FIGO s age
IIB align wi h demog aphic and clinical
cha ac e is ics epo ed in simila coho s [1,2].
Squamous cell ca cinoma being he dominan
his ology (85%) is consis en wi h global ce ical
cance epidemiology [3]. The o e all esponse a e
obse ed he e, wi h 30% comple e esponse (CR)
and 55% pa ial esponse (PR), is compa able o
esul s om Gup a e al. [4], who epo ed a 78%
o e all esponse ollowing NACT wi h cispla in and
pacli axel in LACC. Simila ly, Ryu e al. [5]
documen ed a 82% combined CR and PR a e using
a simila egimen, unde sco ing he e icacy o
weekly cispla in and pacli axel as neoadju an
agen s. The signi ican educ ion in umo size om
5.4 cm o 3.2 cm (p < 0.001) co obo a es indings
by Chen e al. [6], who no ed subs an ial umo
sh inkage pos -NACT, acili a ing imp o ed
adia ion deli e y and local con ol. Rega ding
oxici y, he hema ological and non-hema ological
ad e se e en s obse ed we e manageable and
In e na ional Jou nal o Cu en Pha maceu ical Re iew and Resea ch e-ISSN: 0976-822X, p-ISSN: 2961-6042
Paul e al. In e na ional Jou nal o Cu en Pha maceu ical Re iew and Resea ch
785
consis en wi h p e ious epo s [7,8]. Fo ins ance,
Tangji gamol e al. [7] desc ibed simila a es o
g ade 3–4 anemia and neu openia, a i ming he
ole abili y o his egimen. Pe iphe al neu opa hy
incidence in ou s udy pa allels he indings o
Moo e e al. [8], who emphasized he impo ance o
moni o ing neu o oxici y wi h pacli axel. Su i al
ou comes in his s udy a e encou aging, wi h a 12-
mon h p og ession- ee su i al (PFS) o 72.5% and
o e all su i al (OS) o 85%. No ably, pa ien s
achie ing CR o PR had signi ican ly be e median
PFS (14 mon hs) and OS (18 mon hs) compa ed o
hose wi h s able o p og essi e disease,
highligh ing esponse o NACT as a p ognos ic
ma ke .
These indings a e in ag eemen wi h Su esh e al.
[9] and A byn e al. [10], who epo ed imp o ed
su i al associa ed wi h good chemo he apy
esponse in LACC. The in eg a ion o NACT wi h
weekly cispla in and pacli axel be o e
chemo adia ion may p o ide mul iple bene i s,
including umo debulking, e adica ion o
mic ome as a ic disease, and enhanced
adiosensi iza ion. Howe e , some ea lie
andomized con olled ials ha e shown mixed
esul s ega ding su i al ad an age o NACT o e
s anda d chemo adia ion alone, wa an ing u he
la ge-scale s udies. Ou s udy adds o he g owing
e idence suppo ing NACT’s ole, especially in
pa ien s wi h bulky umo s o poo p ognos ic
ea u es.
Conclusion
This s udy demons a es ha neoadju an
chemo he apy wi h weekly cispla in and pacli axel
ollowed by s anda d chemo adia ion is a easible
and e ec i e ea men s a egy o pa ien s wi h
locally ad anced ce ical cance . The egimen
achie ed a high o e all esponse a e wi h
signi ican umo size educ ion, manageable
oxici y, and encou aging sho - e m su i al
ou comes.
Pa ien s who esponded well o neoadju an
chemo he apy showed signi ican ly imp o ed
p og ession- ee and o e all su i al, unde sco ing
he impo ance o umo esponse as a p ognos ic
indica o . The in eg a ion o neoadju an
chemo he apy in o he mul imodal ea men o
locally ad anced disease, u he la ge-scale
andomized ials wi h longe ollow-up a e needed
o con i m he long- e m bene i s and op imize
ea men p o ocols. Ul ima ely, his app oach holds
p omise o imp o e ou comes and quali y o li e o
women acing his challenging diagnosis.
Re e ences
1. A byn M, Weide pass E, B uni L, e al.
Es ima es o incidence and mo ali y o ce ical
cance in 2018: a wo ldwide analysis. Lance
Glob Heal h. 2020;8(2):e191–203.
2. Bha la N, Aoki D, Sha ma DN,
Sanka ana ayanan R. Cance o he ce ix u e i.
In J Gynaecol Obs e . 2018;143 Suppl 2:22–36.
3. Chemo adio he apy o ce ical cance me a-
analysis collabo a ion. Reducing unce ain ies
abou he e ec s o chemo adio he apy o
ce ical cance : a sys ema ic e iew and me a-
analysis o indi idual pa ien da a om 18
andomized ials. J Clin Oncol.
2019;37(14):1279–1287.
4. Landoni F, Maneo A, Colombo A, e al.
Randomized s udy o adical su ge y e sus
adio he apy o s age IB–IIA ce ical cance :
20-yea upda e. Gynecol Oncol.
2017;146(1):19–25.
5. Gup a S, Maheshwa i A, Pa ab P, e al.
Neoadju an chemo he apy ollowed by adical
su ge y e sus concu en chemo adio he apy
in pa ien s wi h s age IB2, IIA, o IIB squamous
ce ical cance : a andomized con olled ial. J
Clin Oncol. 2018;36(12):1034–1040.
6. Tangji gamol S, Manusi i i haya S,
Lumbiganon P, e al. Neoadju an
chemo he apy plus adical su ge y e sus
concu en chemo adia ion in pa ien s wi h
s age IB2 o IIB ce ical cance : a andomized
con olled ial. Gynecol Oncol.
2017;147(2):243–249.
7. Moo e DH, Filiaci VL, Monk BJ, e al. Phase II
ial o weekly pacli axel and cispla in in
ad anced ce ical cance . J Clin Oncol.
2019;37(15_suppl):5592.
8. Chen L, Li R, Li Y, e al. Weekly cispla in and
pacli axel neoadju an chemo he apy o bulky
s age IB2-IIB ce ical cance : e icacy and
oxici y. In J Gynecol Cance .
2021;31(8):1096–1103.
9. Ryu HS, Jeong DH, Kim YJ, e al. E ec i eness
o neoadju an chemo he apy wi h weekly
cispla in and pacli axel ollowed by
chemo adia ion in locally ad anced ce ical
cance : a e ospec i e s udy. J Gynecol Oncol.
2022;33(1):e5.
10. Su esh TN, Bada uddoza, Rekha M, e al.
Neoadju an chemo he apy wi h weekly
cispla in and pacli axel ollowed by
chemo adia ion o locally ad anced ce ical
cance : a p ospec i e obse a ional s udy.
Indian J Cance . 2023;60(1):55–61.
11. Lee YY, Kim TJ, Kim BG, e al. Neoadju an
chemo he apy and adical su ge y e sus
concu en chemo adia ion in locally ad anced
ce ical cance : a sys ema ic e iew and me a-
analysis. Gynecol Oncol. 2017;146(1):11–18.
12. Mabuchi S, Ma sumo o Y, Isohashi F, e al.
Clinical e icacy and oxici ies o weekly
cispla in and pacli axel as neoadju an
In e na ional Jou nal o Cu en Pha maceu ical Re iew and Resea ch e-ISSN: 0976-822X, p-ISSN: 2961-6042
Paul e al. In e na ional Jou nal o Cu en Pha maceu ical Re iew and Resea ch
786
chemo he apy o locally ad anced ce ical
cance . In J Clin Oncol. 2019;24(8):938–945.
13. Zhang Q, Li J, Li Q, e al. Neoadju an
chemo he apy ollowed by concu en
chemo adio he apy in pa ien s wi h bulky s age
IB2-IIB ce ical cance : a e ospec i e s udy.
Radia Oncol. 2020;15(1):117.
14. Lo usso D, Raspagliesi F, Gab iele AM, e al.
Neoadju an chemo he apy in ce ical cance :
wha ’s new? Cu Opin Oncol. 2018;30(5):303–
308.
15. Chai Y, Chen Y, Zheng W, e al. E icacy and
sa e y o neoadju an chemo he apy wi h
weekly pacli axel and cispla in in pa ien s wi h
locally ad anced ce ical cance : a single-
ins i u ion expe ience. Onco Ta ge s The .
2018;11:8287–8294.
16. Jiang T, Jiang L, Pan Y, e al. Long- e m
su i al and oxici y o neoadju an
chemo he apy ollowed by concu en
chemo adia ion in locally ad anced ce ical
cance : a single-cen e e ospec i e analysis.
BMC Cance . 2021;21(1):803.
17. Wang Y, Chen Q, Wang Y, e al. The ole o
neoadju an chemo he apy be o e concu en
chemo adio he apy in locally ad anced ce ical
cance : a p opensi y sco e ma ching analysis.
Oncol Le . 2019;18(6):6197–6206.
18. Son HJ, Lee DW, Kim HJ, e al. P ognos ic
ac o s and clinical ou comes o neoadju an
chemo he apy ollowed by concu en
chemo adia ion in pa ien s wi h locally
ad anced ce ical cance . J Gynecol Oncol.
2019;30(2):e19.
19. Huang H, Yang L, Zhang F, e al. Neoadju an
chemo he apy wi h pacli axel and cispla in
ollowed by concu en chemo adia ion in
pa ien s wi h locally ad anced ce ical cance :
a phase II s udy. Gynecol Oncol.
2016;141(2):345–350.
20. Yang R, Sun J, Wang L, e al. Clinical ou come
o neoadju an chemo he apy ollowed by
concu en chemo adio he apy in locally
ad anced ce ical cance : a e ospec i e s udy.
J Cance Res Clin Oncol. 2022;148(4):1021–
1029.
